Healthcare

Saluda Medical (ASX:SLD), which trades on the ASX through CHESS Depository Interests, is one of the more differentiated medical-device names available to Australian investors. The company develops closed-loop spinal cord stimulation systems for chronic pain, using technology designed to sense the spinal cord’s physiological …

BlinkLab (ASX:BB1) is building a digital-health platform aimed at addressing one of the more persistent challenges in neurodevelopmental care: access to timely and scalable assessment.

The company is focused on the OncoSil device, which delivers radioactive phosphorus-32 microparticles directly into pancreatic tumours as a form of targeted internal radiation therapy.

Mesoblast (ASX:MSB) has reached a markedly different stage of development after years in which itsInvestmentcase depended largely onClinical Trialsand regulatory outcomes.

Paradigm Biopharmaceuticals (ASX:PAR) remains one of the ASX's more binary healthcare stories: a clinical-stage biotech whose value is tied largely to a single drug programme and its progression through late-stage trials. The market is effectively waiting on data and funding clarity rather than pricing …

Neuren Pharmaceuticals (ASX:NEU) occupies an unusual position on the ASX: a biotechnology company that is already generating meaningful cash from an approved product while advancing a pipeline aimed at rare neurodevelopmental disorders. Its lead product, DAYBUE (trofinetide), is approved in the United States for …

Australian Clinical Labs (ASX:ACL) is one of the country’s three large private pathology providers, and after a difficult couple of years for the sector it is trying to prove that operational discipline can offset a softer revenue backdrop. The company runs a national network …